Primary Job Title Chief Strategy Office Primary Organization 
Hitachi Chemical
Location New York, New York, United States Regions Greater New York Area, East Coast, Northeastern US Gender Male
LinkedIn View on LinkedIn
Robert “Bob” Preti is PCT’s co-founder and the visionary behind its successful growth and development strategy over much of the last two decades. Upon PCT’s acquisition by Hitachi Chemical Co. America, Ltd. (Hitachi Chemical’s consolidated subsidiary) in May 2017, Bob’s role expanded to Chief Executive Officer and President of PCT, responsible for
development, management and oversight of the global business operations of Hitachi Chemical’s regenerative medicine business unit.
Bob built PCT to meet a recognized need for high quality manufacturing and development services in an emerging industry. As the cell therapy field has grown, so too has PCT- the company has now served over 100 Clients and performed more than 20,000 cell therapy procedures. His leadership has been instrumental in creating PCT’s Client-focused model that helps bridge the gap between discovery and patient care through efficient transfer of cell-based therapies from laboratory into clinical practice. His vision for PCT includes expansion of its manufacturing capacity in the U.S., Asia and Europe, as well as the development of new technological and engineering innovations that will help streamline and automate many cell processing techniques, leading to faster scale up, appropriate cost of goods, and robust quality for the industry.
Bob holds a BS degree in biology from Fordham University, and a MS degree and Doctorate, both in biology, from New York University.
